National University of Ireland Galway
|As first author||3|
|As last author||18|
J Mary Murphy(12)
Bernard P. Mahon(10)
Cynthia M. Coleman(6)
Fergal J O'Brien(5)
Garry P Duffy(5)
Roisin M. Dwyer(4)
Michael J. Kerin(4)
James A L Brown(3)
Conn L Hastings(3)
Matthew D Griffin(3)
... and 45 others
These arethe10 unique sources for Frank Barry's 47 publications. A single publication may appear in multiple sources. Click on a name or publication count to see the publications for a particular source.
|Ireland -> Maynooth University||10|
|Ireland -> Maynooth University -> PubMed||3|
|Ireland -> National University of Ireland Galway||24|
|Ireland -> National University of Ireland Galway -> PubMed||22|
|Ireland -> Royal College of Surgeons in Ireland||3|
|Ireland -> Royal College of Surgeons in Ireland -> PubMed||2|
|Ireland -> University College Cork||1|
|Ireland -> University College Cork -> PubMed||1|
|Ireland -> University College Dublin||12|
|Ireland -> University College Dublin -> PubMed||1|
The present invention relates to the use of secreted proteins from mesenchymal stem cells and other cells for the treatment of myocardial infarction. In particular, the invention provides compositions and methods based on secreted proteins from mesenchymal stem cells and the genes encoding them.
The Eph (erythropoietin-producing hepatocellular carcinoma) receptors and their cell surface anchored ligands, the Ephrins, comprise the largest of the receptor tyrosine kinases families with 14 receptors and 8 ligands. The receptors are subdivided into Eph-A and Eph-B categories and have known actions in the development of the vascular and nervous system. The present invention relates to an isolated mesenchymal stem cell selected from the group consisting of an isolated mesenchymal stem cell that expresses Ephrin-B2, an isolated mesenchymal stem cell that over-expresses Ephrin-B2, and an isolated mesenchymal stem cell that is genetically modified to increase Ephrin-B2 expression. The invention further relates to the various applications of the isolated mesenchymal stem cells of the present invention.
Abstract Markers, antibodies and recombinant scFvs for Mesenchymal Stem Cell sub-populations and osteoclasts. The present invention relates to specific epitopes of surface membrane bound glycoproteins expressed by mesenchymal stem cells and pre-osteoclasts and relates to antibodies such as monoclonal antibodies and recombinant scFv or fragments thereof, raised to the particular epitope and their use in identifying, isolating, and characterization of mesenchymal stem cell sub-populations such as that termed "Stromal Progenitor Cells" (SPCs) in bone marrow and identifying, isolating, and characterization of pre-osteoclasts in peripheral blood. By binding to a specific epitope on the cell surface, limbin/EVC-2 detection and separation by conventional cell sorting methodologies are facilitated.
Osteopontin for the prediction and treatment of cardiovascular diseases The present invention relates to the use of endothelial progenitor cells (EPCs) and osteopontin for the treatment of cardiovascular diseases or complications. The invention also relates to the use of EPC osteopontin levels as a marker of the risk of the development of these cardiovascular complications. In particular, the invention provides compositions and methods based on osteopontin and the genes encoding osteopontin.
Clicking through these tabs will give you a wealth of further insights into this expert through their commonly used topics, the evolution of their expertise, their collaborators and their publications.
Here is a quick breakdown of this expert's publication history
If this is the expert you have been looking for, simply click here to make contact.